JPH048408B2 - - Google Patents
Info
- Publication number
- JPH048408B2 JPH048408B2 JP56056869A JP5686981A JPH048408B2 JP H048408 B2 JPH048408 B2 JP H048408B2 JP 56056869 A JP56056869 A JP 56056869A JP 5686981 A JP5686981 A JP 5686981A JP H048408 B2 JPH048408 B2 JP H048408B2
- Authority
- JP
- Japan
- Prior art keywords
- item
- emulsion
- nutrient
- nutritional
- nutrient solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000839 emulsion Substances 0.000 claims abstract description 128
- 235000015097 nutrients Nutrition 0.000 claims abstract description 82
- 238000000034 method Methods 0.000 claims abstract description 51
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 206010021143 Hypoxia Diseases 0.000 claims abstract description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 58
- 210000001519 tissue Anatomy 0.000 claims description 57
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 56
- 239000001301 oxygen Substances 0.000 claims description 56
- 239000012530 fluid Substances 0.000 claims description 45
- 235000016709 nutrition Nutrition 0.000 claims description 42
- 239000000243 solution Substances 0.000 claims description 36
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 33
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 31
- 210000004556 brain Anatomy 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 26
- 239000000126 substance Substances 0.000 claims description 26
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical group FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 23
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 15
- 238000000502 dialysis Methods 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 13
- 239000003792 electrolyte Substances 0.000 claims description 11
- 230000002503 metabolic effect Effects 0.000 claims description 10
- 238000000527 sonication Methods 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 9
- 239000001569 carbon dioxide Substances 0.000 claims description 9
- 239000004615 ingredient Substances 0.000 claims description 9
- 210000000278 spinal cord Anatomy 0.000 claims description 9
- -1 fluoride ions Chemical class 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 238000006213 oxygenation reaction Methods 0.000 claims description 8
- 235000012041 food component Nutrition 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 6
- 230000001804 emulsifying effect Effects 0.000 claims description 6
- 239000011591 potassium Substances 0.000 claims description 6
- 108010001478 Bacitracin Proteins 0.000 claims description 5
- 229960003071 bacitracin Drugs 0.000 claims description 5
- 229930184125 bacitracin Natural products 0.000 claims description 5
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N Isoleucine Chemical compound CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 239000003797 essential amino acid Substances 0.000 claims description 4
- 235000020776 essential amino acid Nutrition 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims description 2
- 229930182847 D-glutamic acid Natural products 0.000 claims description 2
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims description 2
- 229930182819 D-leucine Natural products 0.000 claims description 2
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 claims description 2
- 229930182818 D-methionine Natural products 0.000 claims description 2
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 2
- 229930182832 D-phenylalanine Natural products 0.000 claims description 2
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 claims description 2
- 229930182822 D-threonine Natural products 0.000 claims description 2
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims description 2
- 229930182831 D-valine Natural products 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 10
- 230000003115 biocidal effect Effects 0.000 claims 4
- 239000002243 precursor Substances 0.000 claims 4
- 235000014633 carbohydrates Nutrition 0.000 claims 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 claims 1
- 239000000356 contaminant Substances 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 238000002525 ultrasonication Methods 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 abstract description 11
- 238000004945 emulsification Methods 0.000 abstract description 4
- 230000037361 pathway Effects 0.000 abstract description 4
- 238000002405 diagnostic procedure Methods 0.000 abstract description 3
- 230000004087 circulation Effects 0.000 description 24
- 230000006378 damage Effects 0.000 description 24
- 238000002474 experimental method Methods 0.000 description 21
- 230000010412 perfusion Effects 0.000 description 19
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 14
- 210000003169 central nervous system Anatomy 0.000 description 12
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 11
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 11
- 239000007789 gas Substances 0.000 description 11
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 230000002490 cerebral effect Effects 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 241000239290 Araneae Species 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 208000028867 ischemia Diseases 0.000 description 9
- 230000029058 respiratory gaseous exchange Effects 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000001537 neural effect Effects 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 229920001983 poloxamer Polymers 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 241000282326 Felis catus Species 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 208000020431 spinal cord injury Diseases 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 210000002226 anterior horn cell Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 5
- 230000007954 hypoxia Effects 0.000 description 5
- 210000003140 lateral ventricle Anatomy 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 229920002545 silicone oil Polymers 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000004884 grey matter Anatomy 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000002232 neuromuscular Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 210000000115 thoracic cavity Anatomy 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 210000004885 white matter Anatomy 0.000 description 4
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 3
- 102000013563 Acid Phosphatase Human genes 0.000 description 3
- 108010051457 Acid Phosphatase Proteins 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010053648 Vascular occlusion Diseases 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000011067 equilibration Methods 0.000 description 3
- 230000002008 hemorrhagic effect Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000021331 vascular occlusion disease Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- 208000036982 Spinal cord ischaemia Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010047163 Vasospasm Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002473 artificial blood Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 231100000516 lung damage Toxicity 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000004783 oxidative metabolism Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004895 regional blood flow Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 208000037974 severe injury Diseases 0.000 description 2
- 230000009528 severe injury Effects 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000007556 vascular defect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000021657 Birth injury Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010051093 Cardiopulmonary failure Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- QIZAPOPOGYXZCW-UHFFFAOYSA-N FOF.[C] Chemical compound FOF.[C] QIZAPOPOGYXZCW-UHFFFAOYSA-N 0.000 description 1
- 208000034308 Grand mal convulsion Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 229920001774 Perfluoroether Polymers 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 206010053649 Vascular rupture Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 210000002551 anterior cerebral artery Anatomy 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 238000013131 cardiovascular procedure Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 238000002710 external beam radiation therapy Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000007946 glucose deprivation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000001299 hyperoxygenation Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 210000000876 intercostal muscle Anatomy 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000005230 lumbar spinal cord Anatomy 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 1
- IMBXEJJVJRTNOW-XYMSELFBSA-N methylprednisolone succinate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC(O)=O)CC[C@H]21 IMBXEJJVJRTNOW-XYMSELFBSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 229940038504 oxygen 100 % Drugs 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 210000003388 posterior cerebral artery Anatomy 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 210000002301 subretinal fluid Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000000287 tissue oxygenation Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000004855 vascular circulation Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
- A61M2202/0476—Oxygenated solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/3653—General characteristics of the apparatus related to heating or cooling by Joule effect, i.e. electric resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Nutrition Science (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/139,886 US4378797A (en) | 1980-04-14 | 1980-04-14 | Extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1278305A Division JPH02198562A (ja) | 1980-04-14 | 1989-10-25 | 組織酸素低下および虚血性障害治療のための酸素添加合成栄養物の脈管外循環装置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5718608A JPS5718608A (en) | 1982-01-30 |
| JPH048408B2 true JPH048408B2 (en]) | 1992-02-17 |
Family
ID=22488738
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5686981A Granted JPS5718608A (en) | 1980-04-14 | 1981-04-14 | Intervascular circulation of oxygen addition synthetic nutrient for treatment of tissu oxygen reduction and ischemic disease |
| JP1278305A Granted JPH02198562A (ja) | 1980-04-14 | 1989-10-25 | 組織酸素低下および虚血性障害治療のための酸素添加合成栄養物の脈管外循環装置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1278305A Granted JPH02198562A (ja) | 1980-04-14 | 1989-10-25 | 組織酸素低下および虚血性障害治療のための酸素添加合成栄養物の脈管外循環装置 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4378797A (en]) |
| EP (1) | EP0037992B1 (en]) |
| JP (2) | JPS5718608A (en]) |
| AT (1) | ATE16243T1 (en]) |
| AU (1) | AU566457B2 (en]) |
| CA (1) | CA1202867A (en]) |
| DE (1) | DE3172743D1 (en]) |
| ZA (1) | ZA812310B (en]) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4445886A (en) * | 1980-04-14 | 1984-05-01 | Thomas Jefferson University | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders |
| US4657532A (en) * | 1985-07-19 | 1987-04-14 | Thomas Jefferson University | Intra-peritoneal perfusion of oxygenated fluorocarbon |
| US4830849A (en) * | 1980-04-14 | 1989-05-16 | Thomas Jefferson University | Extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders |
| US4661092A (en) * | 1983-12-09 | 1987-04-28 | Popovich Robert P | Peritoneal artificial lung |
| JPH0410845Y2 (en]) * | 1987-06-18 | 1992-03-17 | ||
| US4870964A (en) * | 1988-06-16 | 1989-10-03 | Paul F. Bailey, Jr. | Opthalmic surgical device and method with image data reflected off of the eye |
| JP2753846B2 (ja) * | 1989-03-06 | 1998-05-20 | 大成建設株式会社 | 柱コンクリート圧入工法 |
| JPH0433284U (en]) * | 1990-07-13 | 1992-03-18 | ||
| US5584804A (en) * | 1990-10-10 | 1996-12-17 | Life Resuscitation Technologies, Inc. | Brain resuscitation and organ preservation device and method for performing the same |
| US5149321A (en) * | 1990-10-10 | 1992-09-22 | Klatz Ronald M | Brain resuscitation device and method for performing the same |
| US5395314A (en) * | 1990-10-10 | 1995-03-07 | Life Resuscitation Technologies, Inc. | Brain resuscitation and organ preservation device and method for performing the same |
| US5827222A (en) * | 1990-10-10 | 1998-10-27 | Life Resuscitation Technologies, Inc. | Method of treating at least one of brain and associated nervous tissue injury |
| AU3665193A (en) * | 1992-03-20 | 1993-10-21 | Alcon Surgical, Inc. | Fluid flow and pressure control system |
| US5350359A (en) * | 1992-07-16 | 1994-09-27 | Temple University Of The Commonwealth System Of Higher Education | Control, treatment and/or diagnosis of physiological conditions with degassed perfluorocarbon liquid |
| US5335650A (en) * | 1992-10-13 | 1994-08-09 | Temple University - Of The Commonwealth System Of Higher Education | Process control for liquid ventilation and related procedures |
| US6849083B2 (en) * | 1993-02-10 | 2005-02-01 | Radiant Medical, Inc. | Method and apparatus for controlling a patients's body temperature by in situ blood temperature modification |
| US6033383A (en) * | 1996-12-19 | 2000-03-07 | Ginsburg; Robert | Temperature regulating catheter and methods |
| US5837003A (en) * | 1993-02-10 | 1998-11-17 | Radiant Medical, Inc. | Method and apparatus for controlling a patient's body temperature by in situ blood temperature modification |
| US6110168A (en) * | 1993-02-10 | 2000-08-29 | Radiant Medical, Inc. | Method and apparatus for controlling a patient's body temperature by in situ blood temperature modifications |
| US6620188B1 (en) | 1998-08-24 | 2003-09-16 | Radiant Medical, Inc. | Methods and apparatus for regional and whole body temperature modification |
| US5590651A (en) * | 1995-01-17 | 1997-01-07 | Temple University - Of The Commonwealth System Of Higher Education | Breathable liquid elimination analysis |
| US5741248A (en) * | 1995-06-07 | 1998-04-21 | Temple University-Of The Commonwealth System Of Higher Education | Fluorochemical liquid augmented cryosurgery |
| US6030358A (en) | 1997-08-08 | 2000-02-29 | Odland; Rick Matthew | Microcatheter and method for site specific therapy |
| US6110139A (en) * | 1997-10-21 | 2000-08-29 | Loubser; Paul Gerhard | Retrograde perfusion monitoring and control system |
| US6679859B1 (en) * | 1997-10-24 | 2004-01-20 | Alliance Pharmaceutical Corp. | Amelioration of ischemic damage using synthetic oxygen carriers |
| WO1999021541A2 (en) * | 1997-10-24 | 1999-05-06 | Alliance Pharmaceutical Corp. | Amelioration of ischemic damage using synthetic oxygen carriers |
| US6485450B1 (en) | 1998-03-16 | 2002-11-26 | Life Science Holdings, Inc. | Brain resuscitation apparatus and method |
| DE19861012A1 (de) | 1998-03-18 | 1999-09-30 | Pharm Pur Gmbh | Behandlungsmittel für die Ophthalmologie |
| US6338727B1 (en) | 1998-08-13 | 2002-01-15 | Alsius Corporation | Indwelling heat exchange catheter and method of using same |
| US6977140B1 (en) * | 1998-09-29 | 2005-12-20 | Organ Recovery Systems, Inc. | Method for maintaining and/or restoring viability of organs |
| US7749693B2 (en) * | 1998-09-29 | 2010-07-06 | Lifeline Scientific, Inc. | Method of determining that an organ is not suitable for transplantation and using it for testing substances |
| US6673594B1 (en) | 1998-09-29 | 2004-01-06 | Organ Recovery Systems | Apparatus and method for maintaining and/or restoring viability of organs |
| CA2382871A1 (en) | 1999-08-24 | 2001-03-01 | Neuron Therapeutics, Inc. | Lumbar drainage catheter |
| US6500809B1 (en) | 1999-11-12 | 2002-12-31 | Neuron Therapeutics, Inc. | Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith |
| AU4512701A (en) | 1999-12-03 | 2001-06-12 | Neuron Therapeutics, Inc. | Method and apparatus for closed recirculation of synthetic cerebrospinal fluid |
| US6447500B1 (en) | 2000-04-28 | 2002-09-10 | Medtronic, Inc. | Brain fluid ion concentration modification for treating neurological disorders |
| US20040073099A1 (en) * | 2000-04-28 | 2004-04-15 | Medtronic, Inc. | Brain fluid ion concentration modification for treating neurological disorders |
| US7008535B1 (en) | 2000-08-04 | 2006-03-07 | Wayne State University | Apparatus for oxygenating wastewater |
| WO2002085431A2 (en) * | 2001-04-24 | 2002-10-31 | Neuron Therapeutics, Inc. | Method of delivering liquid through cerebral spinal pathway |
| AU2002256332A1 (en) * | 2001-04-24 | 2002-11-05 | Neuron Therapeutics, Inc. | Cassettes supporting intracranial perfusions |
| WO2003020208A2 (en) * | 2001-08-31 | 2003-03-13 | Neuron Therapeutics, Inc. | Treatment of neurologic hemorrhage |
| US20030220675A1 (en) * | 2002-05-21 | 2003-11-27 | Coin C. Gene | Method of cooling the central nervous system |
| US20040064169A1 (en) * | 2002-09-30 | 2004-04-01 | Briscoe Kathleen E. | User interface for medical device |
| US7087075B2 (en) * | 2002-09-30 | 2006-08-08 | Medtronic Emergency Response Systems, Inc. | Feedback system for rapid induction of mild hypothermia |
| US7179279B2 (en) * | 2002-09-30 | 2007-02-20 | Medtronic Physio Control Corp. | Rapid induction of mild hypothermia |
| US7056282B2 (en) * | 2002-12-23 | 2006-06-06 | Medtronic Emergency Response Systems, Inc. | Coolant control for rapid induction of mild hypothermia |
| EP1613153B1 (en) * | 2003-04-04 | 2021-06-02 | Organ Recovery Systems, Inc. | Methods and apparatus for perfusion, diagnosis, storage and/or transport of an organ or tissue |
| EP1613152B1 (en) * | 2003-04-04 | 2018-07-04 | Organ Recovery Systems, Inc. | Device for separating gas from a liquid path |
| US20050027173A1 (en) * | 2003-07-31 | 2005-02-03 | Briscoe Kathleen E. | Brain injury protocols |
| US7640063B2 (en) * | 2004-05-04 | 2009-12-29 | The Cleveland Clinic Foundation | Methods of treating medical conditions by neuromodulation of the cerebellar pathways |
| WO2005107854A2 (en) | 2004-05-04 | 2005-11-17 | The Cleveland Clinic Foundation | Corpus callosum neuromodulation assembly |
| US7346382B2 (en) | 2004-07-07 | 2008-03-18 | The Cleveland Clinic Foundation | Brain stimulation models, systems, devices, and methods |
| US20060034946A1 (en) * | 2004-08-13 | 2006-02-16 | Yanming Wang | Irrigating solution for neurosurgical procedures |
| US20060057065A1 (en) * | 2004-09-11 | 2006-03-16 | Yanming Wang | Composition and method to prevent and treat brain and spinal cord injuries |
| US20060073098A1 (en) * | 2004-10-02 | 2006-04-06 | Yanming Wang | Irrigating solution for neurosurgical procedures |
| US20060128797A1 (en) * | 2004-12-15 | 2006-06-15 | Yanming Wang | Method and composition for resuscitation |
| JP4710005B2 (ja) * | 2005-03-18 | 2011-06-29 | 国立大学法人山口大学 | 生体液中のイオン濃度測定装置 |
| US8535691B2 (en) * | 2006-02-16 | 2013-09-17 | Peach Technologies, LLC. | Perflurochemical treatment process and apparatus |
| US10850235B2 (en) | 2006-10-09 | 2020-12-01 | Minnetronix, Inc. | Method for filtering cerebrospinal fluid (CSF) including monitoring CSF flow |
| US8435204B2 (en) | 2006-10-09 | 2013-05-07 | Neurofluidics, Inc. | Cerebrospinal fluid purification system |
| US10632237B2 (en) | 2006-10-09 | 2020-04-28 | Minnetronix, Inc. | Tangential flow filter system for the filtration of materials from biologic fluids |
| US8419710B2 (en) * | 2006-12-06 | 2013-04-16 | Medtronic, Inc. | Methods for infusing fluids via an implantable infusion system |
| US9220889B2 (en) | 2008-02-11 | 2015-12-29 | Intelect Medical, Inc. | Directional electrode devices with locating features |
| US8019440B2 (en) | 2008-02-12 | 2011-09-13 | Intelect Medical, Inc. | Directional lead assembly |
| US9272153B2 (en) | 2008-05-15 | 2016-03-01 | Boston Scientific Neuromodulation Corporation | VOA generation system and method using a fiber specific analysis |
| US7799016B2 (en) * | 2008-06-20 | 2010-09-21 | Pharmaco-Kinesis Corporation | Magnetic breather pump and a method for treating a brain tumor using the same |
| JP5734295B2 (ja) | 2009-08-27 | 2015-06-17 | ザ クリーブランド クリニック ファウンデーション | 組織活性の部位を推定するためのシステムおよび方法 |
| US8323270B2 (en) * | 2009-10-19 | 2012-12-04 | Pharmaco-Kinesis Corporation | Enhanced method for delivering bevacizumab (avastin) into a brain tumor using an implanted magnetic breather pump |
| US8323269B2 (en) * | 2009-10-19 | 2012-12-04 | Pharmaco-Kinesis Corporation | Metronomic convection enhanced delivery of intrathecal chemotherapy using an implanted magnetic breather pump (MBP) for leptomeningeal carcinomatosis |
| WO2011068997A1 (en) | 2009-12-02 | 2011-06-09 | The Cleveland Clinic Foundation | Reversing cognitive-motor impairments in patients having a neuro-degenerative disease using a computational modeling approach to deep brain stimulation programming |
| WO2011114260A1 (en) | 2010-03-19 | 2011-09-22 | Pfizer Inc. | Cerebrospinal fluid purification system |
| US8913804B2 (en) | 2010-06-14 | 2014-12-16 | Boston Scientific Neuromodulation Corporation | Programming interface for spinal cord neuromodulation |
| WO2012135198A2 (en) | 2011-03-29 | 2012-10-04 | Boston Scientific Neuromodulation Corporation | System and method for image registration |
| US9592389B2 (en) | 2011-05-27 | 2017-03-14 | Boston Scientific Neuromodulation Corporation | Visualization of relevant stimulation leadwire electrodes relative to selected stimulation information |
| US8751008B2 (en) | 2011-08-09 | 2014-06-10 | Boston Scientific Neuromodulation Corporation | Remote control data management with correlation of patient condition to stimulation settings and/or with clinical mode providing a mismatch between settings and interface data |
| EP2879757B1 (en) | 2012-08-04 | 2019-06-26 | Boston Scientific Neuromodulation Corporation | Systems and methods for storing and transferring registration, atlas, and lead information between medical devices |
| EP2890454B1 (en) | 2012-08-28 | 2017-11-08 | Boston Scientific Neuromodulation Corporation | Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines |
| WO2014070290A2 (en) | 2012-11-01 | 2014-05-08 | Boston Scientific Neuromodulation Corporation | Systems and methods for voa model generation and use |
| US9959388B2 (en) | 2014-07-24 | 2018-05-01 | Boston Scientific Neuromodulation Corporation | Systems, devices, and methods for providing electrical stimulation therapy feedback |
| US10272247B2 (en) | 2014-07-30 | 2019-04-30 | Boston Scientific Neuromodulation Corporation | Systems and methods for stimulation-related volume analysis, creation, and sharing with integrated surgical planning and stimulation programming |
| US10265528B2 (en) | 2014-07-30 | 2019-04-23 | Boston Scientific Neuromodulation Corporation | Systems and methods for electrical stimulation-related patient population volume analysis and use |
| EP3204112A1 (en) | 2014-10-07 | 2017-08-16 | Boston Scientific Neuromodulation Corporation | Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters |
| AU2016268259B2 (en) | 2015-05-26 | 2019-01-31 | Boston Scientific Neuromodulation Corporation | Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation |
| US10780283B2 (en) | 2015-05-26 | 2020-09-22 | Boston Scientific Neuromodulation Corporation | Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation |
| WO2017003947A1 (en) | 2015-06-29 | 2017-01-05 | Boston Scientific Neuromodulation Corporation | Systems and methods for selecting stimulation parameters by targeting and steering |
| WO2017003946A1 (en) | 2015-06-29 | 2017-01-05 | Boston Scientific Neuromodulation Corporation | Systems and methods for selecting stimulation parameters based on stimulation target region, effects, or side effects |
| US11147540B2 (en) | 2015-07-01 | 2021-10-19 | Minnetronix, Inc. | Introducer sheath and puncture tool for the introduction and placement of a catheter in tissue |
| AU2016304020B2 (en) | 2015-08-05 | 2019-09-19 | Minnetronix Neuro, Inc. | Tangential flow filter system for the filtration of materials from biologic fluids |
| EP3359252B1 (en) | 2015-10-09 | 2020-09-09 | Boston Scientific Neuromodulation Corporation | System and methods for clinical effects mapping for directional stimulations leads |
| ES2944452T3 (es) | 2015-12-04 | 2023-06-21 | Minnetronix Inc | Sistemas de acondicionamiento de fluido cerebrospinal |
| US10716942B2 (en) | 2016-04-25 | 2020-07-21 | Boston Scientific Neuromodulation Corporation | System and methods for directional steering of electrical stimulation |
| CN109416937A (zh) | 2016-06-24 | 2019-03-01 | 波士顿科学神经调制公司 | 用于临床效果的视觉分析的系统和方法 |
| US10350404B2 (en) | 2016-09-02 | 2019-07-16 | Boston Scientific Neuromodulation Corporation | Systems and methods for visualizing and directing stimulation of neural elements |
| US10780282B2 (en) | 2016-09-20 | 2020-09-22 | Boston Scientific Neuromodulation Corporation | Systems and methods for steering electrical stimulation of patient tissue and determining stimulation parameters |
| JP6828149B2 (ja) | 2016-10-14 | 2021-02-10 | ボストン サイエンティフィック ニューロモデュレイション コーポレイション | 電気刺激システムに対する刺激パラメータ設定の閉ループ決定のためのシステム及び方法 |
| CN110167629B (zh) | 2017-01-03 | 2023-07-18 | 波士顿科学神经调制公司 | 用于选择兼容mri的刺激参数的系统和方法 |
| EP3519043B1 (en) | 2017-01-10 | 2020-08-12 | Boston Scientific Neuromodulation Corporation | Systems and methods for creating stimulation programs based on user-defined areas or volumes |
| US10625082B2 (en) | 2017-03-15 | 2020-04-21 | Boston Scientific Neuromodulation Corporation | Visualization of deep brain stimulation efficacy |
| WO2018187090A1 (en) | 2017-04-03 | 2018-10-11 | Boston Scientific Neuromodulation Corporation | Systems and methods for estimating a volume of activation using a compressed database of threshold values |
| AU2018301355B2 (en) | 2017-07-14 | 2020-10-01 | Boston Scientific Neuromodulation Corporation | Systems and methods for estimating clinical effects of electrical stimulation |
| EP3634569A1 (en) | 2017-08-15 | 2020-04-15 | Boston Scientific Neuromodulation Corporation | Systems and methods for controlling electrical stimulation using multiple stimulation fields |
| EP3784331B1 (en) | 2018-04-27 | 2023-01-18 | Boston Scientific Neuromodulation Corporation | Multi-mode electrical stimulation systems and methods of making and using |
| WO2019210214A1 (en) | 2018-04-27 | 2019-10-31 | Boston Scientific Neuromodulation Corporation | Systems for visualizing and programming electrical stimulation |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3516410A (en) * | 1968-01-03 | 1970-06-23 | Salomon Hakim | Cerebro-ventricular catheter |
| US3583387A (en) * | 1968-12-20 | 1971-06-08 | John T Garner | Pressure absorbing appliance for treating hydrocephalus |
| US3626950A (en) * | 1970-06-19 | 1971-12-14 | Heyer Schulte Corp | Catheter with augmented drainage means |
| US3669116A (en) * | 1970-07-06 | 1972-06-13 | Heyer Schulte Corp | Drainage catheter with anticlogging means |
| US3669094A (en) * | 1970-07-06 | 1972-06-13 | Heyer Schulte Corp | Device and method for measuring intracranial pressure |
| US3690323A (en) * | 1970-12-01 | 1972-09-12 | Us Army | Device for draining ventricular fluid in cases of hydrocephalus |
| US3946731A (en) * | 1971-01-20 | 1976-03-30 | Lichtenstein Eric Stefan | Apparatus for extracorporeal treatment of blood |
| US3753865A (en) * | 1971-03-12 | 1973-08-21 | Univ California | Method and apparatus for preserving human organs extracorporeally |
| US3823091A (en) * | 1971-05-19 | 1974-07-09 | Green Cross Corp | Stable emulsion of fluorocarbon particles |
| SE393537B (sv) * | 1973-07-20 | 1977-05-16 | Stille Werner Ab | Anordning for inforande och styrning av en kateter eller liknande i haligheter eller blodkerl i kroppen pa en patient |
| JPS5331209B2 (en]) * | 1973-10-05 | 1978-09-01 | ||
| FR2249657B1 (en]) * | 1973-11-07 | 1977-04-15 | Ugine Kuhlmann | |
| US3894541A (en) * | 1974-02-27 | 1975-07-15 | El Shafei Ismail Lotfy | Method of treating hydrocephalus |
| US4163734A (en) * | 1975-05-30 | 1979-08-07 | Radiometer A/S | Reference liquid for blood gas equipment |
| US4148314A (en) * | 1976-10-18 | 1979-04-10 | Baxter Travenol Laboratories, Inc. | Blood pressure alarm system for dialysis machines |
| US4173654A (en) * | 1977-01-03 | 1979-11-06 | California Institute Of Technology | Novel fluorohydrocarbons |
| US4173224A (en) * | 1977-06-02 | 1979-11-06 | Alvin J. Marx | Automated intravenous fluid regulating and administering apparatus |
| US4110474A (en) * | 1977-08-26 | 1978-08-29 | Suntech, Inc. | Tetramethylpentane blood substitutes |
-
1980
- 1980-04-14 US US06/139,886 patent/US4378797A/en not_active Expired - Lifetime
-
1981
- 1981-03-30 CA CA000374217A patent/CA1202867A/en not_active Expired
- 1981-04-03 EP EP81102543A patent/EP0037992B1/en not_active Expired
- 1981-04-03 DE DE8181102543T patent/DE3172743D1/de not_active Expired
- 1981-04-03 AT AT81102543T patent/ATE16243T1/de not_active IP Right Cessation
- 1981-04-07 ZA ZA00812310A patent/ZA812310B/xx unknown
- 1981-04-14 JP JP5686981A patent/JPS5718608A/ja active Granted
-
1985
- 1985-07-17 AU AU45116/85A patent/AU566457B2/en not_active Ceased
-
1989
- 1989-10-25 JP JP1278305A patent/JPH02198562A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| EP0037992A1 (en) | 1981-10-21 |
| US4378797A (en) | 1983-04-05 |
| JPS5718608A (en) | 1982-01-30 |
| ATE16243T1 (de) | 1985-11-15 |
| AU566457B2 (en) | 1987-10-22 |
| ZA812310B (en) | 1982-04-28 |
| DE3172743D1 (en) | 1985-12-05 |
| EP0037992B1 (en) | 1985-10-30 |
| JPH0260347B2 (en]) | 1990-12-17 |
| JPH02198562A (ja) | 1990-08-07 |
| AU4511685A (en) | 1985-10-31 |
| CA1202867A (en) | 1986-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH048408B2 (en]) | ||
| US4830849A (en) | Extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| US4393863A (en) | Extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| US4445500A (en) | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| JPS58185163A (ja) | 発作治療のための組織酸素低下および虚血性障害処置用酸素添加合成栄養物の脈管外循環 | |
| US4686085A (en) | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| US4450841A (en) | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| US4451251A (en) | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| US4446154A (en) | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| US5085630A (en) | Oxygenated fluorocarbon nutrient solution | |
| US4758431A (en) | Extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| US5698536A (en) | Plasma-like substance | |
| US5082831A (en) | Total body washout solution and method of use | |
| US4446155A (en) | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| US4445887A (en) | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| AU717317B2 (en) | Hemodilution facilitated by monitoring oxygenation status | |
| US4445514A (en) | Extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| HK1010448A1 (en) | Facilitated oxygen delivery in conjunction with hemodilution | |
| US4445888A (en) | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders | |
| US5674913A (en) | Method for assisting normal breathing in a mammal having a lung disorder | |
| Kuroda et al. | Successful treatment of fulminating complications associated with extensive rhabdomyolysis by plasma exchange | |
| Henry et al. | The effect of experimental hemorrhagic shock on pulmonary alveolar surfactant | |
| Bocci et al. | Ozonation of blood during extracorporeal circulation. I. Rationale, methodology and preliminary studies | |
| Nagasawa et al. | Effects of a transfusion with a blood substitute (Fluosol-DA, 20%) on cerebral circulation in the monkey | |
| Bilge et al. | Peritoneal oxygenation a feasibility analysis |